Objectives: To examine the ability of flavophospholipol to inhibit bacterial conjugation between Escherichia coli donor and recipient pairs in vitro and in day-of-hatch chickens.
Introduction
The emergence of multidrug-resistant microorganisms is a global problem that has arisen from widespread use of antimicrobials in both human and animal populations. The application of antimicrobials at subtherapeutic levels for disease prophylaxis and growth promotion in poultry and livestock is believed, by some, to increase selection for antimicrobial-resistant populations in the gastrointestinal tract of these animals. [1] [2] [3] The problem is exacerbated because this type of treatment is often applied to large herds or flocks, subsequently creating a large reservoir for antimicrobial-resistant bacteria.
A large, diverse population of facultative and strict anaerobic bacteria live in the gastrointestinal tract 4 and the bacterial genomes of these microorganisms make up the reservoir of potential resistance genes. Localization of resistance genes on mobile genetic elements such as broad-host-range plasmids, transposons and integrons facilitates horizontal transfer of genetic material between bacteria, providing a rapid means of dissemination at the molecular level. [5] [6] [7] [8] Horizontal transfer of antimicrobial resistance is one of the most significant issues with regard to our ability to curtail the emergence of multidrug-resistant bacteria.
Flavophospholipol (also known as bambermycin, flavomycin and moenomycin) is a phosphoglycolipid antibiotic that has been approved for use as a feed additive, to improve nutritional performance and intestinal health, in poultry, swine and cattle. 9 ,10 It primarily acts against Gram-positive bacteria, but it has been shown to reduce shedding of Salmonella in experimentally infected broilers 10 and has also been shown to inhibit growth of Gram-negative bacteria carrying certain R plasmids. Inhibitory specificity against bacteria carrying some R plasmids may explain the apparent inhibition of conjugation in vitro and the decrease in antimicrobial-resistant enteric bacteria in vivo. [11] [12] [13] Flavophospholipol is the only known feed additive to have been described with the potential to reduce horizontal dissemination of resistance genes. 12 In the past 30 years of use, no transferable form of resistance against flavophospholipol has been definitively described, and cross-resistance to therapeutic antimicrobials has not be observed. 9, 12 Most of the in vivo studies, performed to date, have not specifically examined inhibition of conjugation by colonizing animals with well-characterized donor and recipient pairs. In vitro conjugation studies have shown that pre-incubation of the donor strain with flavophospholipol is necessary to inhibit horizontal transfer of resistance genes. 13 This observation suggested that inducible gene expression was required for the inhibitory effect to be observed. 13 If this holds true in the animal, then continuous feeding of flavophospholipol would be necessary to prevent the horizontal dissemination of resistance.
The objective of the present study was to determine the effect of flavophospholipol on conjugation between well-characterized Escherichia coli donor and recipient pairs in vitro and in day-ofhatch chickens.
Material and methods

E. coli donor and recipient strains
Two donor strains were used in the in vitro studies. Donor strain one (DS1) E. coli CVM828 serogroup 0139, fimbrial type F107, contains a 150 kb conjugative plasmid. The conjugation frequency with E. coli lab strain JM109 was previously determined to be 7.1 · 10 -5 per recipient. E. coli DS1 is positive for a Tn21 transposon and exhibits resistance to ampicillin, chloramphenicol, kanamycin, sulfamethoxazole, tetracycline and trimethoprim/sulfamethoxazole. Donor strain two (DS2) E. coli CVM1548 serogroup O149, fimbrial type K88, contains a 190 kb conjugative plasmid with a Tn21 transposon. E. coli DS2 had a previously determined conjugation frequency of 5.3 · 10 -4 per recipient with JM109. 14 DS2 exhibits antimicrobial resistance to chloramphenicol, kanamycin, sulfamethoxazole and tetracycline. A nalidixic-acid-resistant recipient strain (RS1) was derived from a field strain that did not contain a plasmid and was negative by PCR for Tn21. RS1 was susceptible to all antimicrobials tested except chloramphenicol, cefalotin and nalidixic acid. In conjugation studies using RC1 as a donor, resistance to chloramphenicol and cefalotin could not be transferred.
Determination of antimicrobial susceptibility
The antimicrobial MICs were determined by broth microdilution according to methods described by the Clinical Laboratory Standards Institute (CLSI). Susceptibility testing was performed with the Sensititre Ò automated antimicrobial susceptibility system according to the manufacturer's instructions (Trek Diagnostic Systems, Westlake, OH, USA). NARMS panels (CMV7CNCD) for Gram-negatives were used in the Sensititre system; the following antimicrobials were assayed: amikacin, amoxicillin/clavulanic acid, ampicillin, cefoxitin, ceftiofur, ceftriaxone, cefalotin, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, nalidixic acid, streptomycin, sulfamethoxazole, tetracycline and trimethoprim/sulfamethoxazole. The following ATCC strains were used as controls for antimicrobial susceptibility testing: E. coli 35218, E. coli 25922, Staphylococcus aureus 29213 and Pseudomonas aeruginosa 27853. Data were interpreted using CLSI breakpoints, 15 as described previously. 16 
Bacterial conjugation in vitro
The experimental design consisted of three groups. In group I, the primary monoculture consisted of donor cells (DS1 or DS2) grown overnight at 37 C in tryptic soy broth (TSB) containing 0, 2, 4, 8, 16, 32 or 64 mg/L flavophospholipol (Intervet, Inc., Millsboro, DE, USA) and 32 mg/L oxytetracycline followed, on day 2, by no treatment during the secondary conjugation co-culture. In group II, flavophospholipol (0, 2, 4, 8, 16, 32 or 64 mg/L) was present only during the secondary conjugation co-culture (day 2), but not during the primary culture (day 1). In group III, the concentrations used above were present during both the primary and secondary cultures. RS1 was grown overnight in 32 mg/L nalidixic acid for all experiments.
Bacterial conjugation in vivo
On day 2, primary donor and recipient mono-cultures were washed three times in TSB to remove residual antimicrobial treatments. The secondary broth conjugation co-cultures were made by mixing washed DS1 or DS2 cells (0.05 mL) from the overnight cultures with washed RS1 cells (0.5 mL) in 4.95 mL of fresh TSB. All conjugation combinations were incubated overnight at 37 C. Tenfold serial dilutions were spread plated and enumerated on tryptic soy agar (TSA) plates containing oxytetracycline (32 mg/L) and nalidixic acid (32 mg/L). Oxytetracycline was used to select for horizontal transfer of the plasmid, and nalidixic acid was used to counter-select against donor cells. Conjugation frequency per recipient was expressed by dividing the number of transconjugants by the initial number of recipients. Due to the complexity of the in vivo system the number of transconjugants obtained was expressed as cfu/mL rather than by conjugation frequency per recipient.
Experimental birds
Cobb · Ross day-of-hatch broiler chickens were obtained from a local hatchery. All chickens were placed in rearing pens at appropriate rearing temperature on clean pine shavings litter material. Chickens were provided water and a corn-soy based diet that met or exceeded National Research Council guidelines (1994) for ad libitum consumption. A United States Department of Agriculture Institutional Animal Care and Use protocol was followed during the study (IACUC no. 2004009 ).
In vivo experimental design
Day-of-hatch broiler chickens were separated into seven groups, A-G (20 birds/treatment). Group A received untreated feed. Groups B, C, D, E, F and G received medicated feed with 2, 4, 8, 16, 32 and 64 g/ton flavophospholipol, respectively. Analytical analysis of the flavophospholipol content in the feed was 86-88% of the theoretical level as analysed by Eurofins (Memphis, TN, USA). The feed treatments were provided for ad libitum consumption throughout the trials. Cloacal swabs were performed on all birds for 3 days prior to inoculation with donor and recipient strains to assure they were free of nalidixic-acid-resistant and oxytetracycline-resistant Gramnegative bacteria. Cloacal swabs were plated on MacConkey Agar (Difco, Detroit, MI, USA) containing nalidixic acid, oxytetracycline and both nalidixic acid and oxytetracycline. On day 4, 0.25 mL each of E. coli DS2 (donor) and E. coli 1578 nal (recipient) strains were administered via oral gavage to all birds at 10 7 and 10 9 cfu/mL, respectively. Birds were swabbed daily to determine the presence of the donor and recipient and transconjugant populations. All groups were euthanized on day 10.
Bacterial culture from in vivo specimens
To quantitatively measure donor, recipient and transconjugant E. coli populations the caeca were removed and 0.25 g of the caecal contents was placed in 2.25 mL of PBS. Ten-fold serial dilutions of caecal contents were performed in TSB and plated on MacConkey agar with oxytetracycline, nalidixic acid and both oxytetracycline and nalidixic acid. Culture plates were incubated at 37 C for 24 h. Following incubation donor, recipient and transconjugant colonies were counted and transconjugant stock cultures were saved for phenotypic and genotypic characterization.
Molecular analysis of transconjugants
All 80 in vivo and 10 in vitro transconjugants were examined by PFGE and compared with DS2 and RS1 to confirm clonality to the RS1 recipient strain. Chromosomal DNA was digested with XbaI (New England BioLabs, Beverly, MA, USA) according to the standard CDC protocol. Electrophoresis was performed using a CHEF Mapper XA Pulsed Field Gel Electrophoresis System (Bio-Rad Laboratories, Richmond, CA, USA) with 0.5· TBE running buffer C. Gels were stained with ethidium bromide and band patterns were analysed using Molecular Analysis Fingerprinting Software, version 1.6 (Bio-Rad Laboratories, Hercules, CA, USA), using the unweighted pair group method arithmetic average (UPGMA).
To determine whether the Tn21 transposon carried on the DS2 plasmid was transferred to the transconjugants PCR analysis was performed using Tn21-f and intI1-r primers as described previously. 16 
Statistical analysis
Differences in bacterial populations (cfu/mL) were statistically evaluated using the GLM procedure for one-way ANOVA (Sigma Stat, SPSS, Inc. Chicago, IL, USA). Replicate experiments performed in vivo on different dates were significantly different and were not pooled. Differences among mean values were considered significant at P < 0.05 level of significance.
Results
Effect of flavophospholipol on pure cultures
To determine possible combinations for donor and recipient pairs and because high levels of flavophospholipol may effect the growth of some Gram-negative bacteria, the effect of flavophospholipol on overnight growth of each strain was examined. Flavophospholipol treatment significantly reduced the DS1 overnight population at 8, 16, 32 and 64 mg/L and the DS2 overnight population at 16, 32 and 64 mg/L (Table 1) . Flavophospholipol significantly reduced the recipient strain RS1 overnight population at 64 mg/L and the JM109 nal laboratory strain at 32 and 64 mg/L.
In vitro conjugation study
Because RS1 was a field strain, rather than a lab adapted strain, it was chosen as the recipient for all subsequent conjugation studies. Preliminary conjugation studies showed that flavophospholipol treatment of the overnight recipient RS1 culture (2, 4, 8, 16 , 32 or 64 mg/L) had no effect on the conjugation frequency obtained from unmedicated conjugations (data not shown). Untreated control conjugation frequencies for donor stains DS1 and DS2 were 8.1 · 10 -4 and 8.2 · 10 -4 per recipient cell, respectively.
In group I, incubation of only the overnight culture with flavophospholipol, there was no significant difference in the number of transconjugants obtained between any of the flavophospholipol treatments and the untreated control. In study groups II and III, a dose-dependent reduction in the transconjugant populations was observed for both donor strains DS1 and DS2 (Figure 1a and b, respectively) . The most significant inhibition occurred in group III experiments when flavophospholipol treatment was present during both overnight and conjugation cultures. No transconjugants were obtained at any flavophospholipol dose from DS1 group III experiments (Figure 1a) . In DS2 group III experiments, the transconjugant populations at 2 and 4 mg/L flavophospholipol dropped to 2.9 log 10 and 1.7 log 10 cfu/mL, respectively, as compared with the untreated control at 8.66 log 10 cfu/mL, and no transconjugants were observed at flavophospholipol dosages above 4 mg/L (Figure 1b) .
In vivo conjugation study DS2 was chosen as the donor strain for in vivo experiments. No nalidixic acid resistance was observed from cloacal swabs taken daily prior to inoculation with DS2 and RS1; however, up to two birds per group were colonized with a tetracycline resistance Gram-negative strain. Daily post-inoculation cloacal swabs showed that both DS2 and RS1 colonized all birds in all experiments and were present for the duration of each study. At the conclusion of the study both DS2 and RS1 were isolated from all Flavophospholipol reduces conjugation frequency in vitro, but not in vivo caecal samples at 7.0-8.0 log 10 cfu/mL in all experiments. There was no significant difference in the number of transconjugants isolated from chickens among any of the flavophospholipol treatment groups when compared with the untreated controls (P ‡ 0.05) ( Table 2) .
Susceptibility profiles and molecular analysis of transconjugants
A total of 5 transconjugants from each in vivo study group (n = 80) and 10 transconjugants from in vitro conjugations of DS2 and RS1 were genotypically analysed by PFGE and compared with DS2 and RS1 (data not shown). All transconjugants examined from in vitro and in vivo studies were clonal to RS1 as predicted. All the in vitro transconjugants were positive for the Tn21 transposon as determined by PCR analysis (data not shown). The susceptibility profile of transconjugants isolated from the in vitro conjugation of DS2 and RS1 demonstrated the expected susceptibility profile with resistance to six of the antimicrobials tested (cefalotin, chloramphenicol, kanamycin, nalidixic acid, sulfamethoxazole and tetracycline). The kanamycin resistance gene carried by DS2 did not confer cross-resistance to gentamicin.
The susceptibility profiles of the 80 transconjugants selected from the in vivo studies were much more complex. The number of antimicrobials these isolates were resistant to ranged from 4 to 11, suggesting that RS1 acquired resistance traits from normal chicken gastrointestinal flora. The phenotypes correlated to the date each experiment was performed, rather than feed treatment (Table 3) . Only 2 of the 80 transconjugants carried the identical susceptibility profile generated in vitro with DS2 and RS1. Four other transconjugants that also displayed resistance to 11 antimicrobials exhibited resistance to sulfamethoxazole, suggesting that they may have acquired the DS2 plasmid in combination with another plasmid. Seven (8.75%) of the transconjugants acquired the kanamycin, sulfamethoxazole and tetracycline combination carried by DS2; two of these transconjugants were in the untreated control of study three. One hundred per cent of the transconjugants exhibited tetracycline and nalidixic acid resistance because oxytetracycline and nalidixic acid were used for selection and counter-selection in all of the conjugations.
Forty-five of the transconjugants (56%) exhibited gentamicin resistance. Gentamicin resistance that did not confer cross-resistance to kanamycin was prevalent in the first two studies. In the third study, resistance to both gentamicin and kanamycin was present; this may have represented an aminoglycoside resistance gene not present on DS2 donor plasmid that conferred crossresistance to both gentamicin and kanamycin. In the fourth study, all transconjugants were susceptible to gentamicin and 75% were susceptible to kanamycin. A total of 34% and 29% of the transconjugants in the study displayed resistance to ampicillin and amoxicillin/clavulanic acid, respectively.
Transconjugants from studies two and four carried fewer phenotypic resistance traits per isolate than studies one and three. In study three, 80% of the transconjugants displayed resistance to 10 or 11 of the antimicrobials tested. The susceptibility profiles exhibited by transconjugants isolated from untreated controls were also observed in the treated birds regardless of flavophospholipol dosage.
The Tn21 transposon is very common in Gram-negative bacteria and was in present in 90%, 100% and 100% of the transconjugants from studies one, two and three, respectively. In study four, three of the five control group transconjugants carried Tn21; however, none from flavophospholipol treatment groups carried the Tn21 transposon.
For the present study the number and molecular weight of plasmids carried by the transconjugants were not determined. It is possible that multiple plasmids were acquired in vivo making it difficult to determine whether flavophospholipol specifically inhibited conjugation between DS2 and RS1. The possibility of gene transfer by transducing phage was not examined. However, it is apparent that flavophospholipol was unable to inhibit acquisition, by the recipient, of mobile genetic elements conferring multidrug resistance.
Discussion
Although flavophospholipol is only approved for use in poultry at 2 g/ton, higher doses were used due to previous reports that flavophospholipol antimicrobial activity may be inactivated in the gut. 17 A product that inhibited bacterial conjugation and did not select for antimicrobial resistance would be a useful feed additive and might decrease dissemination of resistance genes in the gastrointestinal reservoir. To date flavophospholipol has not been shown to select for any known transferable mechanism of resistance. 12 Poppe et al. 18 showed that horizontal transfer of a conjugative plasmid carrying multiple antimicrobial resistance genes could occur in the avian gastrointestinal tract without selection pressure. Under the conditions used in the present study, transconjugants were also readily obtained in vivo without selection pressure. This study attempted to inhibit conjugative transfer between known donor and recipient pairs using an antimicrobial growth promoter in vivo.
Flavophospholipol treatment of donor but not recipient broth cultures in vitro produced significant reductions in the number of transconjugants observed. A reduction of the transconjugant population was observed when the donor cultures were incubated in the presence of flavophospholipol during the conjugation portion of the experiments. A slightly greater reduction was observed when the overnight donor and conjugation cultures were incubated with flavophospholipol. This is consistent with previous results that suggested an inducible inhibition was responsible. 13 Flavophospholipol treatment only during the initial overnight incubation had no effect on the number of transconjugants produced as compared with the untreated controls when DS2 was used as the donor. Because the donor cells were washed to remove residual flavophospholipol prior to the conjugation culture and the conjugation culture was allowed to incubate overnight, the donor cells were probably able to overcome an induced Table 3 . The profile given in boldface was identical to the expected profile generated from conjugation between donor DS2 and RS1.
inhibitory effect. In addition, daughter cells produced during the overnight incubation would never have been exposed to flavophospholipol. During preliminary experiments performed with only a 2 h conjugation incubation time as previously described, 13 very few transconjugants were produced in untreated controls and none was produced in the flavophospholipol-treated groups. Consequently, the 2 h broth incubation was extended overnight.
It has been reported that high levels of flavophospholipol can affect the growth of cells that are normally intrinsically resistant. 17 A 100-fold reduction in cell growth was observed for DS1 from the overnight culture incubated with 64 mg/L flavophospholipol. The reduction in the transconjugant population obtained from 64 mg/L flavophospholipol-treated DS1 may reflect the lower number of donor cells in the subsequent conjugation inoculum.
The transconjugants isolated from in vitro conjugations using DS2 all exhibited the predicted susceptibility phenotype with resistance to six antimicrobials. Acquired resistances to kanamycin, sulfamethoxazole and tetracycline were the phenotypic markers that suggested the DS2 plasmid had been horizontally transferred. The phenotypic resistance to kanamycin displayed by DS2 did not confer cross-resistance to gentamicin.
The most significant observation of the present study was that flavophospholipol did not prevent recipient E. coli from acquiring naturally occurring resistance determinants in vivo. It has been suggested that flavophospholipol may alter the structure of fimbriae such that an effective mating pair bridge may not occur. 13 The results from the in vitro studies suggest that the effect of flavophospholipol was on the donor but not on the recipient E. coli.
In the chicken caeca there was no significant difference in the number of transconjugants observed between any of the flavophospholipol treatments and the untreated controls run on the same date. However, the susceptibility profiles of the chicken transconjugants analysed suggest that plasmids present in the native microflora may have been transferred alone or in combination with the DS2 plasmid. The multidrug susceptibility profiles correlated to the date the birds were obtained from the local hatchery and not the flavophospholipol treatment.
Only 2.5% of the chicken transconjugants possessed a susceptibility phenotype identical to that obtained from in vitro conjugations. Only four additional transconjugants, which also displayed resistance to 11 antimicrobials, exhibited resistance to the kanamycin-sulfamethoxazole-tetracycline phenotype provided by DS2. Sulfamethoxazole appeared to be the best indicator that DS2 may have transferred its plasmid. Resistance to sulfamethoxazole was only exhibited by 8.75% of the chicken transconjugants. Since no selection pressure was used during the in vivo experiments, the DS2 plasmid may have sustained point mutations, deletions or recombination events that could have changed the phenotypic susceptibility profile. However, this was not observed among the 10 transconjugants examined from in vitro conjugations.
Gentamicin resistance was prevalent among the chicken transconjugants isolated in vivo. This was not surprising since gentamicin is present as a preservative in some poultry vaccines. Resistance to ampicillin and amoxicillin/clavulanic acid was not exhibited by DS2 and was likely provided by the normal flora. Tn21 was highly prevalent, 76.25%, among the chicken transconjugants. If only six of the transconjugants acquired the DS2 plasmid, it is likely that Tn21 was acquired from the normal flora.
Because the donor and recipient strains colonized the birds so well, it is surprising that the donor phenotype was not isolated more frequently. A number of factors could explain this. It is possible that the transconjugants obtained from transfer of the DS2 plasmid were not as fit as transconjugants that acquired naturally occurring plasmids. It is also possible that mutations or recombination events may have occurred masking the identity of markers used in the study. Further molecular characterization of the plasmids, transposons and integrons would be necessary to completely rule out these possibilities. It is possible that the low percentage acquisition of the donor phenotype was due to inhibition by flavophospholipol; however, the donor phenotype was largely absent in the untreated control groups as well.
